Neobiosis Announces FDA Approval of IND for Use of ViXomeTM in COVID-19 ‘Post COVID Syndrome’

Neobiosis, A UF Accelerate resident client, is a leading research and manufacturing biotechnology company focused on pioneering the development of novel therapeutics from perinatal tissues as a new class of medicines. Today, Neobiosis announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for ViXome™, its drug for the treatment of 'Post COVID Syndrome (AKA "Long Haul COVID Syndrome").

Dialectic Therapeutics Receives FDA Clearance of IND Application for for Its Lead Product Candidate To Treat Cancer

UF startup Dialectic Therapeutics, Inc., a Texas-based biotechnology company focused on creating innovative new technologies to treat cancer, announced that the U.S. Food and Drug Administration (FDA) has concluded that Dialectic may proceed with its clinical investigation for its lead product candidate, DT2216, a unique compound built using its proprietary and novel Antiapoptotic Protein Targeted Degradation (APTaD) technology.

Pear, etectRx To Explore Use of Sensors To Help Patients Stick With Digital Therapeutics

Pear Therapeutics is teaming up with UF Innovate | The Hub startup etectRx in a "first of its kind" collaboration examining the use of digital pill solutions with prescription digital therapeutics (PDTs), the latter company announced. As part of the agreement, whose financial terms were not disclosed, the companies will work on developing up to two central nervous system product candidates combining PDTs and adherence sensors.

Abbott Blood Test To Evaluate Mild Concussions Wins FDA Clearance

Doctors soon will have a new way to evaluate patients with concussions: a rapid blood test made by Abbott Laboratories that has been cleared by the U.S. Food and Drug Administration. It’s an advancement that could eliminate the need for some patients to get costly CT scans and the radiation exposure that accompanies them.